Coffee and tea consumption, patient‐reported, and clinical outcomes in a longitudinal study of patients with breast cancer
Year: 2022
Type: article
Abstract: BACKGROUND: Higher consumption of coffee and tea has been associated with improved health outcomes in the general population and improved breast cancer (BC) prognosis. This study investigated patterns of coffee and tea consumption and association with patient-reported outcomes (PROs) and clinical outcomes among survivors of BC. METHODS: The authors included survivors of stage I-III BC enrolled in the CANTO cohort (NCT01993498) that provided post-treatment assessment of coffee and tea consumption from years 1 to 4 after diagnosis. Group-based trajectory modeling clustered patients according to daily consumption of coffee and tea. Multivariable mixed models and Cox models examined associations between consumption, PROs and clinical outcomes. RESULTS: Among 3788 patients, the authors identified four stable patterns of consumption: "Low" (25.8%), "Moderate" (37.6%), "High" (25.3%), and "Very high" (11.3%), corresponding to <1, 2, 3, and ≥ 4 cups of coffee and/or tea per day. Patients in the "Very high" group (vs. "Low"), were more likely to be younger, smokers, with higher monthly income and education. PROs and survival outcomes were similar across the four groups. CONCLUSIONS: Over one in three survivors of BC reported high or very high consumption of coffee and/or tea. The authors found no association between higher consumption of coffee and/or tea, worse PROs and clinical outcomes.
Source: Cancer
DOI: 10.1002/cncr.34401
Authors: Davide Soldato, Julie Havas, Tracy E. Crane, Daniele Presti, Pietro Lapidari, Nathalie Rassy, Barbara Pistilli, Elise Martin, Lucia Del Mastro, Anne‐Laure Martin, Alexandra Jacquet, Charles Coutant, Paul Cottu, Asma Merimeche, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Fabrice André, Ines Vaz‐Luis, Antonio Di Meglio
Language: English
Topic: Coffee research and impacts
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,600
OpenAlex ID: W4289260824
